Sino Biopharm's application for clinical trials of innovative drugs TQB2103 (Claudin18.2 ADC) was accepted by the CDE Release time:2023-02-10On February 10, Sino Biopharm announced that its self-developed Class 1 new drug, TQB2103 (Claudin18.2 ADC), has submitted an application to the Center...
Biopharmaceutics & Drug Dispositionpublishes original review articles, short communications, and reports in biopharmaceutics, drug disposition, pharmacokinetics and pharmacodynamics, especially those that have a direct relation to the drug discovery/development and the therapeutic use of drugs. These includes:...
EMA's committee gave recommendations for marketing authorization of 17 drugs in December, which include therapies for rare heart conditions, anemia, and liver disease. AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline ...
Boosting the development of new drugs in China and serving human health MORE Boosting the development of new drugs in China and serving human health MORE Patents 200+ Innovative Pipeline 30+ Phase I-III & NDA 10+ R&D personnel 400+ More ...
Founded in 2006, Immunotech is the first domestic pharmaceutical company to develop cellular immunotherapy products. It went public on the Hong Kong Stock Exchange in 2020. The company's facility is the largest of its kind producing cellular immunotherapy drugs in China, covering an area of nearly...
The Journal publishes original reports of studies in biopharmaceutics drug disposition and pharmacokinetics especially those which have a direct relation to the therapeutic use of drugs. This includes human pharmacological studies and therapeutic response and toxicity related to plasma and tissue concentrations...
This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs. How Modularization and Digital Delivery are Transforming Pharma Manufacturing Jordan Ulrich;Dana Tilley ...
EMA's committee gave recommendations for marketing authorization of 17 drugs in December, which include therapies for rare heart conditions, anemia, and liver disease. AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline ...
In this collection we follow the progress of key nucleic acid-based drugs, technologies and developing companies, whilst exploring the dealmaking trends driving these emerging therapeutics. Image: Kateryna Kon / Science Photo Library. Collection | 18 October 2024 Antibody developments Discover what...
Dr. Ma Jian, co-founder and CEO of XtalPi, said, "Anti-tumor drug research and development has a very high social value, but also a very high technical difficulty. After the release of the "Clinical Value Oriented Clinical R&D Guidelines for Antineoplastic Drugs" by the State Drug Administr...